Technetium-99m exametazime (HMPAO)

Approved Use: 

• As an adjunct in the detection of altered regional cerebral perfusion in stroke
• Leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease 

​Dose: 

• Cerebral scintigraphy: 10 - 20 mCi
• Tc-99m labeled leukocytes: 7 - 25 mCi

---

Brand Name: Ceretec™
Manufacturer: GE Healthcare

Package Insert (non-stabilized kit)
How Supplied: 5 vial kit
NDC#: 17156-022-05

Package Insert (stabilized kit)
How Supplied: 

• 5 vials of 0.5 mg exametazime
  
• 5 vials of 0.2 mg cobalt stabilizer solution

NDC#: 17156-025-05

Letter from Manufacturer November 2018 (new formulation)
Old Formulation Discontinued March 2019

---

Manufacturer: Jubilant Radiopharma
Package Insert
​How Supplied:​ 5 vial kit 
​NDC #: 65174-200-05

---

Clinical Guidelines:

• ACR-SPR Practice Parameter for the Performance of Scintigraphy for Inflammation and Infection (2018)
• ACR-SPR Practice Parameter for the Performance of SPECT Brain Perfusion and Brain Death Examinations (2016)
• SNMMI Procedure Standard for Brain Death Scintigraphy 2.0 (2012)
• ​EANM Guidelines for Labeling of Leukocytes with Tc-99m HMPAO (2010)
• ​SNMMI Procedure Standard for Brain Perfusion SPECT Using Tc-99m Radiopharmaceuticals 3.0 (2009)
• SNMMI Procedure Standard for Tc-99m HMPAO-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation 3.0 (2004)